{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T19:47:23Z","timestamp":1649188043310},"reference-count":16,"publisher":"FapUNIFESP (SciELO)","issue":"2A","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"published-print":{"date-parts":[[1999,6]]},"abstract":"<jats:p>Apresentamos breve revis\u00e3o da literatura sobre os agonistas dopamin\u00e9rgicos. Referimos os cinco receptores conhecidos e onde est\u00e3o localizados, as vantagens e as desvantagens de sua utiliza\u00e7\u00e3o nos pacientes com a doen\u00e7a de Parkinson.Introduzidos com o objetivo principal de controlar as limita\u00e7\u00f5es da levodopa, aumentando a janela terap\u00eautica, analisamos a farmacocin\u00e9tica, a efic\u00e1cia e os efeitos colaterais da cabergolina, do ropinirole e do pramipexole.<\/jats:p>","DOI":"10.1590\/s0004-282x1999000200029","type":"journal-article","created":{"date-parts":[[2005,4,15]],"date-time":"2005-04-15T14:24:16Z","timestamp":1113575056000},"page":"329-332","source":"Crossref","is-referenced-by-count":1,"title":["Novos agonistas dopamin\u00e9rgicos"],"prefix":"10.1590","volume":"57","author":[{"given":"JAMES PIT\u00c1GORAS DE","family":"MATTOS","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio de Janeiro"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00c2NIA MARIA DE B. CORR\u00caA","family":"MATTOS","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1212\/WNL.45.3_Suppl_3.S5","article-title":"Dopamine agonists in the treatment of Parkinson's disease","volume":"45","author":"Poewe W","year":"1995","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1212\/WNL.45.3_Suppl_3.S6","article-title":"The rationale for the use of dopamine agonist in Parkinson's disease","volume":"45","author":"Jenner P","year":"1995","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.45.3_Suppl_3.S13","article-title":"Pergolide in the treatment of Parkinson's disease","volume":"45","author":"Mizuno Y","year":"1995","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1212\/WNL.45.3_Suppl_3.S28","article-title":"Dopamine agonists in Parkinson's disease","volume":"45","author":"Wolters E","year":"1995","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1212\/WNL.49.1_Suppl_1.S34","article-title":"The role of dopamine agonists in the early Parkinson's disease","volume":"49","author":"Watts RL","year":"1997","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref6","series-title":"Doen\u00e7a de Parkinson: aspectos cl\u00ednicos e cir\u00fargicos","first-page":"97","volume-title":"Tratamento medicamentoso da doen\u00e7a de Parkinson","author":"Barbosa ER","year":"1996"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-6147(92)90025-2","article-title":"Molecular biology of dopamine receptors","volume":"13","author":"Sibley DR","year":"1992","journal-title":"Trends Pharmacol Sci","ISSN":"http:\/\/id.crossref.org\/issn\/0165-6147","issn-type":"print"},{"key":"ref8","first-page":"19","article-title":"The role of D1 and D2 dopamine receptors in motor behavior of patients with Parkinson's disease","volume":"3","author":"Wolters EC","year":"1996","journal-title":"Eur J Neurol","ISSN":"http:\/\/id.crossref.org\/issn\/1351-5101","issn-type":"print"},{"key":"ref9","first-page":"28","article-title":"Dopamine receptors and psychosis","author":"Seelman P","year":"1995","journal-title":"Scientific Amer"},{"key":"ref10","series-title":"Current Trends in the treatment of Parkinson's disease","first-page":"93","volume-title":"Pergolide: clinical experience","author":"Jankovic J","year":"1992"},{"key":"ref11","first-page":"64","article-title":"Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind, L-dopa controled trial","volume":"12","author":"Rinne UK","year":"1997","journal-title":"Mov Disord","ISSN":"http:\/\/id.crossref.org\/issn\/0855-3185","issn-type":"print"},{"key":"ref12","series-title":"Condutas em neurologia","first-page":"241","volume-title":"Avan\u00e7os terap\u00eauticos na doen\u00e7a de Parkinson","author":"Barbosa ER","year":"1997"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.49.1_Suppl_1.S2","article-title":"Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview","volume":"49","author":"Stern MB","year":"1997","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1212\/WNL.49.1_Suppl_1.S58","article-title":"Pharmacologic profile of ropinirole: a nonergoline dopamine agonist","volume":"49","author":"Tulloch IF","year":"1997","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1997.03550020057038","article-title":"Safety and efficacy of pramipexole in early Parkinson's disease: a randomized dose-rating study","volume":"278","year":"1997","journal-title":"JAMA","ISSN":"http:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1212\/WNL.49.3.724","article-title":"Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease","volume":"49","author":"Shannon KM","year":"1997","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v57n2a\/1492.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T16:29:16Z","timestamp":1550075356000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X1999000200029&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,6]]},"references-count":16,"journal-issue":{"issue":"2A","published-print":{"date-parts":[[1999,6]]}},"alternative-id":["S0004-282X1999000200029"],"URL":"https:\/\/doi.org\/10.1590\/s0004-282x1999000200029","relation":{},"ISSN":["0004-282X"],"issn-type":[{"value":"0004-282X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,6]]}}}